Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers

Journal of Immunotherapy

Volumn 27, Issue 1, 2004, Pages 60-72

  Tsuda, Naotake ^a   Mochizuki, Kazuo ^a   Harada, Mamoru ^a   Sukehiro, Aki ^a   Kawano, Koichiro ^a   Yamada, Akira ^a   Ushijima, Kimio ^b   Sugiyama, Toru ^b   Nishida, Takashi ^b   Yamana, Hideaki ^b   Itoh, Kyogo ^b   Kamura, Toshiharu ^b  

^a Obstetrics and Gynecology of Atlanta   (United States)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gynecologic cancer; Immunotherapy; Peptide; Vaccination

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; IMMUNOGLOBULIN G; PEPTIDE DERIVATIVE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER IMMUNOTHERAPY; CELL ASSAY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SCREENING; EDEMA; ENDOMETRIUM CANCER; ERYTHEMA; FEMALE; FEVER; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; INJECTION SITE; LYMPHADENOPATHY; LYMPHOCYTE COUNT; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; RECTUM HEMORRHAGE; RECURRENT CANCER; SIDE EFFECT; SKIN DISEASE; STEM CELL; TUMOR REGRESSION; UTERINE CERVIX CANCER; UTERUS SARCOMA; VACCINATION;

ADULT; AGED; CANCER VACCINES; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MIDDLE AGED; OVARIAN NEOPLASMS; SKIN TESTS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, SUBUNIT;

EID: 0347915729     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200401000-00006     Document Type: Article

References (26)

1. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997; 81:267-268.
2. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999; 10:281-287.
3. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999; 35:946-952.
4. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 1998; 4:2103-2109.
5. Muderspach L, Wilcznski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000; 6:3406-3416.
6. Kikuchi M, Nakao M, Inoue Y, et al. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer. 1999; 81:459-466.
7. Nakao M, Shichijo S, Imaizumi T, et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol. 2000; 164:2565-2574.
8. Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A-24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. 1999; 59:4056-4063.
9. Gomi S, Nakao M, Niiya F, et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. J Immunol. 1999; 163:4994-5004.
10. Harashima N, Tanaka K, Sasatomi T, et al. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol. 2001; 31:323-332.
11. Nishizaka S, Gomi S, Harada K, et al. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res. 2000; 60:4830-4837.
12. Kawano K, Gomi S, Tanaka K, et al. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer. Cancer Res. 2000; 60:3550-3558.
13. Ito M, Shichijo S, Miyagi Y, et al. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer. 2000; 88:633-639.
14. Tamura M, Nishizaka S, Maeda Y, et al. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res. 2001; 92:762-767.
15. Imai N, Harashima N, Ito M, et al. Identification of lck-derived peptides capable of inducing HLA-A2-restricted tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer. 2001; 94:237-242.
16. Ito M, Shichijo S, Tsuda N, et al. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res. 2001; 61:2038-2046.
17. Tanaka S, Tsuda N, Kawano K, et al. Expression of tumor-rejection antigens in gynecological cancers. Jpn J Cancer Res. 2000; 91:1177-1184.
18. Hida N, Maeda Y, Katagiri K, et al. A new culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 2002; 51:219-228.
19. Suzuki N, Maeda Y, Tanaka S, et al. Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer. 2002; 98:45-50.
20. Maeda Y, Hida N, Niiya F, et al. Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients. Br J Cancer. 2002; 87:796-804.
21. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med. 1998; 187:277-288.
22. Ohkouchi S, Yamada A, Imai N, et al. Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens. 2002; 59:259-272.
23. Gohara R, Imai N, Rikimaru T, et al. Phase I clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J Immunother. 2002; 25:439-444.
24. Scheibenbogen C, Lee KH, Stevanovic S, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFN gamma-ELISPOT assay. Int J Cancer. 1997; 71:932-936.
25. Pass HA, Schwarz SL, Wunderlich JR, et al. Immunization of patients with melanoma peptide vaccines: immunogenic assessment using the ELISPOT assay. Cancer J Sci Am. 1998; 4:316-323.
26. Parker DC. T cell-dependent B-cell activation. Ann Rev Immunol. 1993; 11:331-340.